Students Profiles
Return to student list
Research Interests:
I am studying potential
therapies for systemic
lupus erythematosus,
an autoimmune
disease commonly
affecting skin, kidneys
and joints. We are looking at T cell function and the effects
of the drug Rapamycin in the treatment of
the disease.
Fellowship:
David is the recipient of an NIH Predoctoral Fellowship. His work is entitled "Role of the mTOR Pathway in T cell Dysfunction in SLE" and was awarded through the Institute of Arthritis and Musculoskeletal and Skin Diseases.
Publications:
Fernandez D, Perl A. Metabolic Control of T cell activation and death in SLE. Autoimmun Rev. Jan;8(3):184-9, 2009.
Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, Perl A. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. Feb 15;182(4):2063-73, 2009.
Nagy, G., Koncz, A., Fernandez, D. and Perl A. Nitric oxide, mitochondrial hyperpolarization, and T-cell activation. Free Radic. Biol. Med. 42: 1625-1631, 2007.
Perl, A., Nagy, G., Koncz, A., Gergely, P., Fernandez, D., Doherty, E., Telarico, T., Bonilla, E. and Phillips, P.E. (2008) Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity 41(4):287-97, 2008 Review.
Fernandez D, Bonilla E, Mirza, N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54(9):2983-8. 2006.
Nagy G, Ward J, Mosser, DD, Koncz, A, Gergely P JR, Stancato C, Oian Y, Fernandez, D, Niland,B, Grossman CE, Telarico, T, Banki K, Perl A. Regulation of CD4 expression via recycling by HRES-1RAB4 controls susceptibility to HIV infection. J Biol Chem 281:34574-34591, 2006. Fernandez, D., Bonilla, Phillips, P.E. and Perl, A. Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocrin, Metabolic & Immune Disorders - Drug Targets. 6: 305-311, 2006
| 
